RE:RE:RE:RE:No value for PipelineThey said they got the letter to go a head with NASH phase 3 but need to adjust the protocol so I am not sure why we still put probability rate on it.
Even if the EMA's approval is questionable that alone shouldn't rush them to close a low ball deal as the whole NASH was questionable just before the good PR.
The good PR stated record sales when nobody would bet on it, many questioned company's ability to run two trials at the same time well they start the oncology in March and projected to start the NASH with or without Europe in Q3 just few months later.
I think the PR even without Europe was overall very good so they should let the market absorb the news and promote the good news followed by decent SP appreciation before pull the trigger on the dilution.
They just got it all wrong, even if NASH Europe is a no go the overall progress was very good it's either the company incorrectly anticipated a bad reaction to the good PR or a very conservative board didn't have the stomach to wait.
Again just 10 days ago we didn't even know whether they have submitted any of the protocols and the NASH as per some posters would have no chance for straight phase 3!!!